Becton, Dickinson and Company (BDX) Projected to Post Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $3.00 per share and revenue of $5.13 billion for the quarter. Becton, Dickinson and Company has set its FY 2025 guidance at 14.250-14.600 EPS and its FY25 guidance at $14.25-14.60 EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business's quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the company posted $3.42 EPS. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Up 0.6 %

Shares of NYSE:BDX traded up $1.44 during mid-day trading on Thursday, reaching $248.34. 1,401,884 shares of the stock were exchanged, compared to its average volume of 1,959,710. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $250.91. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock's 50 day simple moving average is $229.59 and its 200-day simple moving average is $233.55. The company has a market cap of $72.02 billion, a P/E ratio of 41.81, a P/E/G ratio of 1.72 and a beta of 0.39.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.68%. Becton, Dickinson and Company's payout ratio is presently 70.03%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

BDX has been the subject of a number of research analyst reports. StockNews.com cut shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $283.00.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the company's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares of the company's stock, valued at $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.